CN103689590A - 一种辅助降血脂的保健食品及其制备方法 - Google Patents
一种辅助降血脂的保健食品及其制备方法 Download PDFInfo
- Publication number
- CN103689590A CN103689590A CN201310631349.0A CN201310631349A CN103689590A CN 103689590 A CN103689590 A CN 103689590A CN 201310631349 A CN201310631349 A CN 201310631349A CN 103689590 A CN103689590 A CN 103689590A
- Authority
- CN
- China
- Prior art keywords
- extract
- health food
- agar
- preparation
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013402 health food Nutrition 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 210000004369 blood Anatomy 0.000 title abstract description 16
- 239000008280 blood Substances 0.000 title abstract description 16
- 230000001603 reducing effect Effects 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 24
- 229920001817 Agar Polymers 0.000 claims abstract description 16
- 235000010419 agar Nutrition 0.000 claims abstract description 16
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 14
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 14
- 241001092040 Crataegus Species 0.000 claims abstract description 7
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 7
- 241000196324 Embryophyta Species 0.000 claims abstract description 4
- 239000008272 agar Substances 0.000 claims abstract description 4
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract 2
- 230000002402 anti-lipaemic effect Effects 0.000 claims description 19
- 241000206672 Gelidium Species 0.000 claims description 12
- 235000010443 alginic acid Nutrition 0.000 claims description 12
- 229920000615 alginic acid Polymers 0.000 claims description 12
- 241000748223 Alisma Species 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 8
- 235000020717 hawthorn extract Nutrition 0.000 claims description 7
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 6
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 6
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 6
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 6
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 6
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 6
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 6
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 6
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 6
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 241000206607 Porphyra umbilicalis Species 0.000 claims description 3
- 241000195474 Sargassum Species 0.000 claims description 3
- 241001261505 Undaria Species 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 48
- 150000002632 lipids Chemical class 0.000 abstract description 19
- 235000012000 cholesterol Nutrition 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 14
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 230000029142 excretion Effects 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 235000014493 Crataegus Nutrition 0.000 abstract 1
- 230000000214 effect on organisms Effects 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
- 239000000661 sodium alginate Substances 0.000 abstract 1
- 235000010413 sodium alginate Nutrition 0.000 abstract 1
- 229940005550 sodium alginate Drugs 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 description 16
- 108010023302 HDL Cholesterol Proteins 0.000 description 12
- 108010028554 LDL Cholesterol Proteins 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 235000013305 food Nutrition 0.000 description 9
- 235000013325 dietary fiber Nutrition 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 201000005577 familial hyperlipidemia Diseases 0.000 description 6
- 241001065361 Gynostemma Species 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 4
- 241000786103 Steatomys pratensis Species 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 229960002855 simvastatin Drugs 0.000 description 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241001474374 Blennius Species 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- RNXZPKOEJUFJON-UHFFFAOYSA-N aurantio-obtusin Chemical compound CC1=C(O)C(OC)=C2C(=O)C3=C(O)C(OC)=C(O)C=C3C(=O)C2=C1 RNXZPKOEJUFJON-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229930187479 gypenoside Natural products 0.000 description 2
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- -1 trihydroxy trimethyl glutaryl Chemical group 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- NLOAQXKIIGTTRE-JSWHPQHOSA-N Alisol b acetate Chemical compound O([C@@H]1[C@@H](OC(C)=O)C[C@@H](C)C=2CC[C@]3(C)[C@@]4(C)CC[C@H]5C(C)(C)C(=O)CC[C@]5(C)[C@@H]4[C@@H](O)CC3=2)C1(C)C NLOAQXKIIGTTRE-JSWHPQHOSA-N 0.000 description 1
- NLOAQXKIIGTTRE-UHFFFAOYSA-N Alisol-B-Monoacetat Natural products C=12CC(O)C3C4(C)CCC(=O)C(C)(C)C4CCC3(C)C2(C)CCC=1C(C)CC(OC(C)=O)C1OC1(C)C NLOAQXKIIGTTRE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- PHPUXYRXPHEJDF-UHFFFAOYSA-N oxyphenisatine acetate Chemical group C1=CC(OC(=O)C)=CC=C1C1(C=2C=CC(OC(C)=O)=CC=2)C2=CC=CC=C2NC1=O PHPUXYRXPHEJDF-UHFFFAOYSA-N 0.000 description 1
- 229950000967 oxyphenisatine acetate Drugs 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/256—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Botany (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种用于辅助降血脂的保健食品及其制备方法,主要由以下原料配方组成:琼胶、褐藻胶、山楂、绞股蓝、泽泻、决明子。本发明通过限定该保健食品的成分及配比,以及各中药提取物的制备方法,使其可以抑制胆固醇的吸收,促进胆固醇及甘油三酯的***,减少小肠对脂质的吸收,从而从多方位达到降血脂的效果。此外,本发明的所有原料均为天然植物原料,具有原料来源广、成本低、对机体无毒副作用等优点,能有效降低高血脂患者的血脂水平,遏制动脉粥样硬化。
Description
技术领域
本发明涉及保健食品技术领域,具体涉及一种以琼胶、褐藻胶为主,以中药为辅的辅助降血脂的保健食品,本发明还涉及该保健食品的制备方法。
背景技术
欧洲心脏病学会2013(ESC2013)上报告了血脂异常国际研究(DYSIS)中国中期研究的结果,表明尽管接受了降脂药物(LLD)治疗,但仍有较大比例的患者,尤其是心血管风险较高的患者存在持续性血脂异常。研究结果提示,仍迫切需要优化降脂治疗方案。
脂肪代谢或运转异常使血浆中血脂含量高于正常范围时称为高血脂症。高血脂是冠心病、心肌梗死等心血管病最严重的危险因素。增高的血脂可以说是血管中的“垃圾”,尤其是低密度脂蛋白胆固醇和甘油三酯增高会对血管造成严重的破坏,是引起冠心病、心梗的“元凶”。目前,临床上的调脂药物有:(1)三羟基三甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂(他汀类);(2)苯氧芳酸类(贝特类);(3)胆酸螯合剂;(4)烟酸类;(5)选择性胆固醇吸收抑制剂(衣折麦布)。临床上用的西药虽显效快、作用明显,但长期服用,药物毒性大,容易引起肠胃反应、皮肤潮红、头痛、失眠、四肢无力等症状,对肝、肾都有一定的损伤。中药治疗高血脂疗效慢,用药周期长。
膳食纤维(dietary fiber,简称DF)是指不易被人体消化吸收的,以多糖类为主的大分子物质的总称,是由纤维素、果胶类物质、半纤维素和糖蛋白等物质组成的聚合体。它是当前国际上公认的一种功能性食品,被称为除了水、蛋白质、糖类、脂类、维生素、矿物质六大营养素之外的第七营养素。研究表明,常见的动脉粥样硬化、高血压、冠心病、高血脂症都与膳食纤维摄入量不足有关。
膳食纤维的强吸水能力可使肠道中粪便的体积增大,加快其转运速度,减少其中有害物质接触肠壁的时间;其中的木质素能吸收胆汁酸,果胶能结合胆固醇,从而达到减少肠壁对胆固醇的吸收,加快胆固醇代谢的作用,在使体内胆固醇含量下降的同时,促进胆汁酸从粪便中排出。
琼胶与褐藻胶都属可溶性膳食纤维,有强吸水性,能吸收肠道中的水分,使肠内容物膨胀,增加大便量;在刺激肠壁,缓解便秘的同时,与胆固醇结合,促进胆固醇分解代谢。山楂,含维生素C、黄酮等成分,具有消食健胃、行气散瘀、化浊降脂之功效;绞股蓝,含有绞股蓝皂苷、人参皂苷等成分,具有消炎解毒、止咳祛痰之功效;泽泻,含有23-乙酰泽泻醇B、24-乙酰泽泻醇A等成分,具有利水渗湿、泄热、化浊降脂之功效;决明子,含有大黄酚、橙黄决明素等成分,具有清热明目、润肠通便之功效。
山楂、绞股蓝、泽泻、决明子,均具有降血脂功效,已被医药界广泛认可。但未见将膳食纤维与中药结合,利用其协同作用来达到降血脂目的的相关报道。因此,发明人将膳食纤维与中药不同配伍,开发辅助降血脂的保健食品具有现实意义。
发明内容
本发明的目的是利用我国传统的医药理论,提供了一种能够辅助降血脂的保健食品,该保健食品成本低、来源广、对机体无副作用,有降低高血脂患者血脂水平的效果。
本发明通过以下技术方案来实现:
一种辅助降血脂的保健食品,其原料包括琼胶0~70wt%,褐藻胶0~70wt%;还包括中药添加物,此中药添加物采用0~50wt%的泽泻提取物。
所述琼胶来源于江蓠、石花菜、伊谷藻或紫菜,所述褐藻胶来源于海带、裙带菜、巨藻、羊栖菜或马尾藻。
上述中药添加物采用0~50wt%的泽泻提取物和0~50wt%的绞股蓝提取物。
上述中药添加物采用0~50wt%的山楂提取物、0~50wt%的绞股蓝提取物和0~50wt%的决明子提取物。
一种辅助降血脂的保健食品的制备方法,将各原料按照重量配比混合,研磨成细末,装入胶囊,每粒0.3-0.6克。
所述山楂提取物或泽泻提取物或绞股蓝提取物或决明子提取物的制备方法如下:将山楂或泽泻或绞股蓝或决明子用体积百分比浓度为0~70%的乙醇水溶液回流提取2~4次,固液比1:5~1:10,每次1~4h,过滤并合并提取液,减压浓缩得浓缩液,-80℃冷冻过夜,冷冻干燥或喷雾干燥。
本发明与现有同类产品相比,具有很好的降血脂效果。其特点在于,将可溶性膳食纤维与中药结合,能有效地发挥二者的协同作用。琼胶、褐藻胶等海藻膳食纤维具有凝胶特性,在肠道内形成凝胶,分隔和阻留胆固醇,影响胆固醇与消化酶、胆汁酸微团与肠黏膜的接触,从而利于脂肪和胆固醇的分解***。同时,海藻膳食纤维可以直接吸附肠道中的胆固醇(TC)、甘油三酯(TG)和粪便胆汁酸(FBA)而随粪便排出体外,减少了TC、TG和FBA的肠道再吸收,加速了胆固醇的分解代谢,阻断胆汁酸肝肠循环,从而使血清TC、TG水平降低。中药山楂中的黄酮可以通过抑制三羟基三甲基戊二酰辅酶A(HMG-CoA)还原酶的活性,来抑制内源性胆固醇的合成。泽泻能影响脂肪的分解,减少乙酰辅酶A的合成,从而影响胆固醇的合成,并且有阻止类脂质在血液内滞留或渗透到肠内壁的能力,促进血液中胆固醇的运输和清除。绞股蓝中的绞股蓝皂苷、人参皂苷等能增加胆固醇的代谢和***,从而降低血液中胆固醇含量。决明子中的大黄素能促进胆固醇的代谢。
本发明的特点还在于,能同时降低血清总胆固醇(TC)、甘油三酯(TG)和低密度脂蛋白胆固醇(LDL-C)水平,并升高高密度脂蛋白胆固醇(HDL-C)水平,降低动脉硬化的风险。
具体实施方式
以下通过具体实施方式进一步描述本发明,但本发明不仅仅限于以下实施例。以下实施例仅限于对本发明的疗效做进一步的说明。
实施例一
一种辅助降血脂的保健食品,其各组分重量百分比为:琼胶50wt%,褐藻胶30wt%,泽泻提取物20wt%。
实施例二
一种辅助降血脂的保健食品,其各组分重量百分比为:琼胶50wt%,褐藻胶30wt%,泽泻提取物8wt%,绞股蓝提取物12wt%。
实施例三
一种辅助降血脂的保健食品,其各组分重量百分比为:琼胶27wt%,褐藻胶27wt%,山楂提取物18wt%,绞股蓝提取物15wt%,决明子提取物13wt%。
实施例四
一种辅助降血脂的保健食品,其各组分重量百分比为:琼胶55%,褐藻胶10%,山楂提取物15%,绞股蓝提取物10%,决明子提取物10%。
本发明中,琼胶来源于江蓠、石花菜、伊谷藻或紫菜,褐藻胶来源于海带、裙带菜、巨藻、羊栖菜或马尾藻。
本发明一种辅助降血脂的保健食品的制备方法,将各原料按照重量配比混合,研磨成细末,装入胶囊,每粒0.3-0.6克。
其中,所述山楂提取物或泽泻提取物或绞股蓝提取物或决明子提取物的制备方法如下:将山楂或泽泻或绞股蓝或决明子用体积百分比浓度为0~70%的乙醇水溶液回流提取2~4次,固液比1:5~1:10,每次1~4h,过滤并合并提取液,减压浓缩得浓缩液,-80℃冷冻过夜,冷冻干燥,粉碎成粉末。或在合并提取液后,将滤液浓缩成相对密度在1.05~1.20之间的浓缩液,再用气流式喷雾干燥成粉末,喷雾干燥机的进口温度150~200℃,出口温度60~80℃。
药效学观察
1.本发明对高血脂症小鼠血脂水平的降低作用。
1.1受试动物
昆明种SD小鼠,雄性,60只,体重20±2g,由福州海王福药制药有限公司提供(许可证号:SCXK(闽)2005~0003)。
1.2小鼠高脂模型的建立及给药
小鼠高脂模型采用高脂饲料致高血脂症法,高脂饲料配方如下:78.8%普通饲料;10.0%猪油;10.0%蛋黄粉;0.2%胆酸钠;1.0%胆固醇。空白组给予普通饲料,其余各组均给予高脂饲料。
小鼠适应性饲养一周后,随机分出12只作为空白组,给予普通饲料,其余48只给予高脂饲料,自由饮食饮水。10d后,眼眶静脉丛取血,测定血清总胆固醇(TC)、总甘油三酯(TG)、高密度脂蛋白胆固醇胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平。根据血清TC水平将小鼠随机分为模型组、辛伐他汀组、实施例一组、实施例二组。
小鼠每天灌胃1次,在灌胃给药的同时每天自由饮食饮水,给药量为10mL·kg-1,连续给药4周。各组分别给予下述受试药物:
实施例一组:灌胃给予本发明实施例一中的保健食品复方;
实施例二组:灌胃给予本发明实施例二中的保健食品复方;
辛伐他汀组:灌胃给予同等剂量的辛伐他汀;
空白组、模型组:灌胃给予同等剂量生理盐水;
1.3检测指标
检测血清中总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)水平。
1.4实验结果
4周后,取血,测定相关指标,结果如表1。
表1本发明保健食品对高脂小鼠血脂的影响
注:与模型组对比,*P<0.05;与模型组对比,**P<0.01。
表1显示,实施例一、实施例二以及辛伐他汀组均能不同程度的降低高脂小鼠TC、TG、LDL-C水平,升高HDL-C水平。与模型组对比,实施例一及实施例二均能极显著性降低高脂小鼠TC、TG、LDL-C水平(P<0.01);实施例二能极显著升高高脂小鼠HDL-C水平(P<0.01),实施例一能显著升高高脂小鼠HDL-C水平(P<0.05)。
如上所述,实施例一及实施例二均能有效降低高脂小鼠血脂水平,具有辅助降血脂的作用。
2.本发明对高血脂症大鼠血脂水平的降低作用。
2.1受试动物
SPF级SD大鼠,雄性,50只,体重200±20g,由福州海王福药制药有限公司提供(许可证号:SCXK(闽)2005~0003)。
2.2大鼠高脂模型的建立及给药
大鼠采用高脂饲料致高血脂症法,高脂饲料配方同小鼠。
适应性饲养一周后,随机分出10只作为空白组,给予普通饲料,其余给予高脂饲料,1~2周后,眼底静脉丛采血,分离血清,检测血清中各项指标。并根据TC分组,每组10只,共4组,分别为:模型组、实施例三高剂量组、实施例三中剂量组和实施例三低剂量组。大鼠每天按10mL·kg-1灌胃1次,灌胃的同时给予高脂饲料,连续给药4周,各组给药剂量如下:
表2实施例三高、中、低剂量组给药剂量(mL·kg-1)
空白组与模型组给予同等剂量的生理盐水,实施例三高、中、低组按照表2灌胃给药。
2.3检测指标
检测血清中总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)水平。
2.4实验结果
表3实施例三对高脂大鼠血脂的影响
注:与模型组对比,*P<0.05;与模型组对比,**P<0.01。
实验结果显示,实施例三高剂量、中剂量组都能极显著降低高脂大鼠血脂水平。
3.结论
综合实验结果,对高血脂动物连续给予不同剂量的本发明30天,各剂量组与模型组对比,均能降低血清总胆固醇、甘油三酯和低密度脂蛋白胆固醇水平,升高高密度脂蛋白胆固醇水平。
依据***《保健食品检验与评价技术规范(2003版)》的判定标准判断,本发明具有辅助降血脂的作用。
Claims (6)
1.一种辅助降血脂的保健食品,其特征在于,其原料包括琼胶0~70wt%,褐藻胶0~70wt%;还包括中药添加物,此中药添加物采用0~50wt%的泽泻提取物。
2.根据权利要求1所述的一种辅助降血脂的保健食品,其特征在于,所述琼胶来源于江蓠、石花菜、伊谷藻或紫菜,所述褐藻胶来源于海带、裙带菜、巨藻、羊栖菜或马尾藻。
3.根据权利要求1所述的一种辅助降血脂的保健食品,其特征在于,上述中药添加物采用0~50wt%的泽泻提取物和0~50wt%的绞股蓝提取物。
4.根据权利要求1所述的一种辅助降血脂的保健食品,其特征在于,上述中药添加物采用0~50wt%的山楂提取物、0~50wt%的绞股蓝提取物和0~50wt%的决明子提取物。
5.根据权利要求1-4任一项所述的一种辅助降血脂的保健食品的制备方法,其特征在于:将各原料按照重量配比混合,研磨成细末,装入胶囊,每粒0.3-0.6克。
6.根据权利要求5所述的一种辅助降血脂的保健食品的制备方法,其特征在于:所述山楂提取物或泽泻提取物或绞股蓝提取物或决明子提取物的制备方法如下:将山楂或泽泻或绞股蓝或决明子用体积百分比浓度为0~70%的乙醇水溶液回流提取2~4次,固液比1:5~1:10,每次1~4h,过滤并合并提取液,减压浓缩得浓缩液,-80℃冷冻过夜,冷冻干燥或喷雾干燥。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310631349.0A CN103689590B (zh) | 2013-11-29 | 2013-11-29 | 一种辅助降血脂的保健食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310631349.0A CN103689590B (zh) | 2013-11-29 | 2013-11-29 | 一种辅助降血脂的保健食品及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103689590A true CN103689590A (zh) | 2014-04-02 |
CN103689590B CN103689590B (zh) | 2016-04-13 |
Family
ID=50351378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310631349.0A Active CN103689590B (zh) | 2013-11-29 | 2013-11-29 | 一种辅助降血脂的保健食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103689590B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104757464A (zh) * | 2015-04-30 | 2015-07-08 | 黄馨莹 | 一种山楂片剂的制作方法 |
CN108272087A (zh) * | 2018-01-30 | 2018-07-13 | 山东汇润膳食堂股份有限公司 | 一种降血脂食品及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1087495A (zh) * | 1993-11-16 | 1994-06-08 | 朱建华 | 低热量保健饮料及其制作方法 |
CN1336193A (zh) * | 2000-07-31 | 2002-02-20 | 雷学军 | 一种含天然药物成份的降血脂功能水及其制作方法 |
CN101095520A (zh) * | 2006-06-26 | 2008-01-02 | 江苏晶隆海洋产业发展有限公司 | 一种具有降脂减肥作用的功能食品 |
CN101613378A (zh) * | 2009-07-17 | 2009-12-30 | 辽宁大学 | 具有减肥与降血脂效果的酸性寡糖及其应用 |
CN101890094A (zh) * | 2010-04-16 | 2010-11-24 | 新疆英惠堂生物科技有限公司 | 一种辅助降血脂的保健品及其制备方法 |
CN102246920A (zh) * | 2011-08-18 | 2011-11-23 | 高益槐 | 一种辅助降血脂的保健食品及其制备方法 |
CN102784254A (zh) * | 2012-03-20 | 2012-11-21 | 河南九势制药股份有限公司 | 一种辅助降血脂的中药组合物及其制备方法 |
-
2013
- 2013-11-29 CN CN201310631349.0A patent/CN103689590B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1087495A (zh) * | 1993-11-16 | 1994-06-08 | 朱建华 | 低热量保健饮料及其制作方法 |
CN1336193A (zh) * | 2000-07-31 | 2002-02-20 | 雷学军 | 一种含天然药物成份的降血脂功能水及其制作方法 |
CN101095520A (zh) * | 2006-06-26 | 2008-01-02 | 江苏晶隆海洋产业发展有限公司 | 一种具有降脂减肥作用的功能食品 |
CN101613378A (zh) * | 2009-07-17 | 2009-12-30 | 辽宁大学 | 具有减肥与降血脂效果的酸性寡糖及其应用 |
CN101890094A (zh) * | 2010-04-16 | 2010-11-24 | 新疆英惠堂生物科技有限公司 | 一种辅助降血脂的保健品及其制备方法 |
CN102246920A (zh) * | 2011-08-18 | 2011-11-23 | 高益槐 | 一种辅助降血脂的保健食品及其制备方法 |
CN102784254A (zh) * | 2012-03-20 | 2012-11-21 | 河南九势制药股份有限公司 | 一种辅助降血脂的中药组合物及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104757464A (zh) * | 2015-04-30 | 2015-07-08 | 黄馨莹 | 一种山楂片剂的制作方法 |
CN108272087A (zh) * | 2018-01-30 | 2018-07-13 | 山东汇润膳食堂股份有限公司 | 一种降血脂食品及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103689590B (zh) | 2016-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Luan et al. | Polysaccharides from Laminaria japonica: An insight into the current research on structural features and biological properties | |
CN101560267B (zh) | 一种多糖***酯的制备方法 | |
CN102008516B (zh) | 一种***的超微粉中药 | |
CN105395919A (zh) | 一种含有黑木耳提取物、具有降血脂作用的组合物及其制备方法 | |
CN103211866A (zh) | 一种用于提高机体免疫力、改善心脑血管功能的软胶囊 | |
CN103689590B (zh) | 一种辅助降血脂的保健食品及其制备方法 | |
CN102151284B (zh) | 一种含褐藻多糖硫酸酯的组合物及其应用 | |
CN101613378B (zh) | 具有减肥与降血脂效果的酸性寡糖及其应用 | |
CN102784247B (zh) | 具有降血脂功能含壳寡糖的药物组合物 | |
CN102640825B (zh) | 一种调节血脂的食品降脂茶冲剂 | |
CN102716414A (zh) | 一种含褐藻多糖硫酸酯的抗肿瘤药物组合物及其制备方法 | |
KR101446277B1 (ko) | 천연약재를 이용한 조성물 및 이의 제조방법 | |
CN104288566B (zh) | 降胆固醇和/或降血脂的中药组合物及其制备方法和应用 | |
CN107594274A (zh) | 一种预防癌症的复合食用菌饮品及其制备方法 | |
JP2004352626A (ja) | 植物由来成分を含有する抗コレステロール剤 | |
Jung et al. | L-ascorbic acid addition to chitosan reduces body weight in overweight women | |
CN102846720B (zh) | 一种降血脂、提高缺氧耐受力的组合物 | |
Andrade et al. | Beta-Glucans as a therapeutic agent: Literature Review | |
CN103503943B (zh) | 一种降脂饼干及其制备方法 | |
KR101201286B1 (ko) | 지방, 탄수화물 및 단백질 흡수억제, 지방 축적 억제 및 지방 분해 효과를 갖는 기능성 조성물과 이를 이용한 식품 | |
CN105193993B (zh) | 一种具有降血脂功效的中药组合物及其制备方法与用途 | |
CN102379904B (zh) | 多糖蛋白片及其制备方法 | |
CN107375847A (zh) | 一种减肥药物、其制备方法及应用 | |
CN106690326A (zh) | 一种复合海藻多糖降血脂口服液及其制备方法 | |
CN1280007A (zh) | 木耳调脂胶囊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |